Revelation Biosciences is a life sciences company whose development of immunologic-based therapies is based on the well-established biology of phosphorylated hexaacyl disaccharide (PHAD) and its effect on the innate immune system. The company announced that it is targeting a new target indication with its Gemini treatment, the prevention of infection in burn patients. This opens up Gemini to a large new market and expands the potential revenue generation of the company.
